Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early Versus Delayed Administration.
Pasqualetti F, Gonnelli A, Molinari A, Cantarella M, Montrone S, Cristaudo A, Baldaccini D, Mattioni R, Delishaj D, Mazzotti V, Morganti R, Cocuzza P, Fabrini MG, Lombardi G, Rudà R, Soffietti R, Paiar F. Pasqualetti F, et al. Among authors: baldaccini d. Anticancer Res. 2018 Oct;38(10):5877-5881. doi: 10.21873/anticanres.12930. Anticancer Res. 2018. PMID: 30275213
Image-guided Stereotactic Body Radiotherapy in Metastatic Prostate Cancer.
Pasqualetti F, Panichi M, Sainato A, Baldaccini D, Cocuzza P, Gonnelli A, Montrone S, Molinari A, Barbiero S, Bruschi A, Notini E, Ursino S, Mazzotti V, Morganti R, Coraggio G, Cantarella M, Erba PA, Paiar F. Pasqualetti F, et al. Among authors: baldaccini d. Anticancer Res. 2018 May;38(5):3119-3122. doi: 10.21873/anticanres.12572. Anticancer Res. 2018. PMID: 29715150
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
Pasqualetti F, Pace A, Gonnelli A, Villani V, Cantarella M, Delishaj D, Vivaldi C, Molinari A, Montrone S, Pellerino A, Franchino F, Baldaccini D, Lombardi G, Lolli I, Catania F, Bazzoli E, Morganti R, Fabi A, Zagonel V, Bocci G, Fabrini MG, Rudà R, Soffietti R, Paiar F. Pasqualetti F, et al. Among authors: baldaccini d. Am J Clin Oncol. 2018 Dec;41(12):1272-1275. doi: 10.1097/COC.0000000000000464. Am J Clin Oncol. 2018. PMID: 29782366
[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer.
Pasqualetti F, Panichi M, Sollini M, Sainato A, Galli L, Morganti R, Chiacchio S, Marciano A, Zanca R, Mannelli L, Coraggio G, Sbrana A, Cocuzza P, Montrone S, Baldaccini D, Gonnelli A, Molinari A, Cantarella M, Mazzotti V, Ricci S, Paiar F, Erba PA. Pasqualetti F, et al. Among authors: baldaccini d. Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):185-191. doi: 10.1007/s00259-019-04482-6. Epub 2019 Oct 16. Eur J Nucl Med Mol Imaging. 2020. PMID: 31620808 Free PMC article.
Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy.
Massaro M, Franceschini D, Spoto R, Dominici L, Franzese C, Baldaccini D, Marini B, di Cristina L, Marzo MA, Lo Faro L, Paganini L, Reggiori G, Galdieri C, Testori A, Scorsetti M. Massaro M, et al. Among authors: baldaccini d. Curr Oncol. 2022 Jul 12;29(7):4893-4901. doi: 10.3390/curroncol29070388. Curr Oncol. 2022. PMID: 35877248 Free PMC article.
Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection.
Franzese C, Perrino M, Marzo MA, Badalamenti M, Baldaccini D, D'Agostino G, Marini B, De Vincenzo F, Zucali PA, Scorsetti M. Franzese C, et al. Among authors: d agostino g, baldaccini d. Clin Exp Metastasis. 2022 Jun;39(3):449-457. doi: 10.1007/s10585-022-10158-7. Epub 2022 Feb 21. Clin Exp Metastasis. 2022. PMID: 35190933
26 results